- Exchange: Munich
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Snapshot for Medicines Co/The (MZN)
| Open: | 26.620 | Day's Range: | 25.585 - 26.620 | Volume: | 1,030 |
|---|---|---|---|---|---|
| Previous Close: | 27.101 | 52wk Range: | 15.631 - 28.537 | 1-Yr Rtn: | +58.65% |
Key Statistics for MZN
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | 23.3646 |
| Relative P/E vs. DAX | - |
| Earnings Per Share (USD) (ttm) | - |
| Est. EPS (USD) (12/2013) | 1.4630 |
| Est. PEG Ratio | 0.7536 |
| Market Cap (M EUR) | 0.00 |
| Shares Outstanding (M) | 0.00 |
| 30 Day Average Volume | 58 |
| Price/Book (mrq) | - |
| Price/Sale (ttm) | - |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 07/25/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for MZN
Company Profile & Key Executives for MZN
The Medicines Company develops products that improve specialized care. The Company markets Angiomax, an anticoagulant approved in the United States and other countries for use in patients undergoing coronary angioplasty procedures.
| Clive A MeanwellChairman/CEO | Glenn P SblendorioPresident/CFO |
| Paul M AntinoriSenior VP/Secy/Gen Cnsl | William B O'ConnorSenior VP/Chief Acctg Officer |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
MZN News
-
Industry News
Advertisement
- 1
- 2
- 3
- 4
- 5
Advertisement
Sponsored Links
Advertisements
Rate this Page